| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.7 | 1.0 |
| Net income | -1.7 | -0.5 |
| EPS (diluted, $ a share) | $-0.72 | $-0.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -29.4% |
|---|---|
| Operating margin | -239.8% |
10-Q filed with the SEC, NASDAQ: XBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Xenetic Biosciences, Inc.: key numbers
- Share price
- $1.49Close, Nov 16
- Market cap
- $3.49M
- Shares outstanding
- 2.34MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xenetic Biosciences, Inc.
All →Xenetic Biosciences M&A Deal with Santersus AG
Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.
- Counterparty
- Santersus AG
“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
Xenetic Biosciences M&A Deal with Santersus AG
Xenetic Biosciences released an updated investor presentation regarding its pending share exchange transaction to acquire Santersus AG. The deal, originally announced on September 16, 2026, involves a proposed acquisition that will result in a combined company focused on advancing NET-targeted therapies for immune-driven diseases and cancer.
- Counterparty
- Santersus AG
Xenetic Biosciences M&A Deal with Santersus AG
Xenetic Biosciences entered into a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction. Upon closing, Santersus shareholders are expected to own approximately 85% of the combined company, which will focus on NET-targeting therapeutics and trade under the new ticker symbol SNTS.
- Counterparty
- Santersus AG
- Earnings call
- Sep 16, 2026, 8:30 AM ET